Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: CARBOPLATIN - ADVERSE EFFECTS , . Treffer: 9

2017

Terbuch, A; Posch, F; Annerer, LM; Bauernhofer, T; Pichler, M; Szkandera, J; Hutterer, GC; Pummer, K; Partl, R; Kapp, KS; Stöger, H; Gerger, A; Stotz, M Long-term cardiovascular complications in stage I seminoma patients.
Clin Transl Oncol. 2017; 19(11):1400-1408 Doi: 10.1007/s12094-017-1742-y [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Sehouli, J; Chekerov, R; Reinthaller, A; Richter, R; Gonzalez-Martin, A; Harter, P; Woopen, H; Petru, E; Hanker, LC; Keil, E; Wimberger, P; Klare, P; Kurzeder, C; Hilpert, F; Belau, AK; Zeimet, A; Bover-Barcelo, I; Canzler, U; Mahner, S; Meier, W Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Ann Oncol. 2016; 27(12):2236-2241 Doi: 10.1093/annonc/mdw418 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Volgger, B; Zeimet, AG; Reinthaller, A; Petru, E; Schauer, C; Klein, M; Sevelda-Schwarzgruber, U; Bogner, G; Wolfram, G; Marth, C Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Int J Gynecol Cancer. 2015; 25(2):257-262 Doi: 10.1097/IGC.0000000000000352 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Stampfl, U; Bermejo, JL; Sommer, CM; Hoffmann, K; Weiss, KH; Schirmacher, P; Schemmer, P; Kauczor, HU; Richter, GM; Radeleff, BA; Longerich, T Efficacy and nontarget effects of transarterial chemoembolization in bridging of hepatocellular carcinoma patients to liver transplantation: a histopathologic study.
J Vasc Interv Radiol. 2014; 25(7):1018-1026 Doi: 10.1016/j.jvir.2014.03.007
Web of Science PubMed FullText FullText_MUG

 

2011

Lee, CK; Gurney, H; Brown, C; Sorio, R; Donadello, N; Tulunay, G; Meier, W; Bacon, M; Maenpaa, J; Petru, E; Reed, N; Gebski, V; Pujade-Lauraine, E; Lord, S; Simes, RJ; Friedlander, M Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
BRIT J CANCER. 2011; 105(3): 360-365. Doi: 10.1038/bjc.2011.256 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2006

Greimel, ER; Bjelic-Radisic, V; Pfisterer, J; Hilpert, F; Daghofer, F; du Bois, A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
J CLIN ONCOL. 2006; 24(4): 579-586. Doi: 10.1200/JCO.2005.02.4067 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Peintinger, F; Georgoulopoulos, A; Ralph, G; Piswanger, C Retrospective comparison of chemotherapy-induced myelotoxicity in patients with ovarian cancer under and over 60 years of age.
J Chemother. 2006; 18(6): 656-661. Doi: 10.1179/joc.2006.18.6.656
Web of Science PubMed FullText FullText_MUG

 

2003

Dalpiaz, O; al Rabi, N; Galfano, A; Martignoni, G; Ficarra, V; Artibani, W Small cell carcinoma of the bladder: a case report and a literature review.
Arch Esp Urol. 2003; 56(2):197-202 (- Case Report)
PubMed

 

1989

Pickel, H; Petru, E; Lahousen, M; Stettner, H; Lehnert, M Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery.
Oncology. 1989; 46(4):222-225 Doi: 10.1159/000226720
Web of Science PubMed FullText FullText_MUG Google Scholar

 

© Med Uni Graz Impressum